All studies
AuthorisedHuman Pharmacology (Phase I)- OtherInterventional

Basket trial for B-cEll driven severe auToimmunE and aLoimmune diseases (chronic Graft vErsUs host diseaSe) treated with anti-CD19 CAR T-cell thErapy

This clinical trial is looking at a new treatment called CD19-CART01 for adults living with severe autoimmune conditions (such as lupus, scleroderma, or myasthenia gravis) or chronic graft-versus-host disease. In these illnesses, immune cells called B cells mistakenly attack healthy parts of the body. CAR T-cell therapy is a modern approach that takes your own immune cells and genetically retrains them in a laboratory to find and clear away these rogue B cells. The cells are then given back to you through a drip. Because this is an early Phase 1 study, the main goal is to find the safest dose and monitor any side effects, such as fever or infections. Doctors will also check if this therapy helps calm the immune system enough to allow patients to reduce or completely stop their daily steroid medications over a 48-week period.

At a glance

Status
Authorised
Phase
Human Pharmacology (Phase I)- Other
Sponsor
Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico, Ospedale Pediatrico Bambino Gesu
Enrolment target
24
Start
29 Sep 2026

What is this study about?

Our immune system usually protects us from illness by fighting off germs. However, in autoimmune diseases and graft-versus-host disease, immune cells called B cells become confused and start attacking healthy tissue. This can cause long-term inflammation and damage to organs, joints, muscles, or nerves. Standard treatments usually rely on steroids and strong immunosuppressants. While these can help, they do not always work well enough and can cause significant long-term side effects.

This trial is testing a promising new approach called CAR T-cell therapy (specifically CD19-CART01). T cells are another type of immune cell that naturally fight off threats. In this study, doctors collect a sample of your T cells and send them to a specialist laboratory. There, the cells are genetically updated to recognise a protein called CD19 found on B cells. When returned to your blood, these 'trained' cells act like a reset button, hunting down and clearing away the harmful B cells causing your disease.

This study is a 'basket trial', which means it tests the same treatment across several different conditions that all share faulty B cells. Because it is in the early stages (Phase 1), the primary aim is safety. Doctors want to see how well the body tolerates the treatment, discover the most effective and safest dose, and make sure the cells can be reliably manufactured in the laboratory.

Researchers will follow participants for at least 48 weeks to see if their symptoms improve, if disease markers in their blood drop, and whether they can safely stop taking daily steroids. If successful, this type of therapy could provide long-lasting relief without the need for constant immunosuppressive tablets.

Key takeaways

  • Phase 1 safety trial testing a personalised cell therapy called CD19-CART01.
  • Aimed at adults with severe autoimmune diseases or chronic graft-versus-host disease.
  • Uses your own reprogrammed immune cells to remove the B cells causing disease.
  • Requires a hospital stay around the time of the infusion for close safety monitoring.
  • Follows participants for at least 48 weeks to check for symptom relief and steroid reduction.
  • Participation is completely voluntary and you can withdraw at any time.

Who may be eligible?

This trial is open to adults aged 18 and older who have been diagnosed with certain severe, long-term conditions driven by faulty B cells. These include severe autoimmune illnesses (such as systemic lupus erythematosus, systemic sclerosis, inflammatory muscle diseases, vasculitis, or myasthenia gravis) as well as chronic graft-versus-host disease following a stem cell or bone marrow transplant.

To be eligible, your condition must be considered active or severe, and standard treatments—such as regular immunosuppressive medicines or steroids—must not have worked well enough to keep your symptoms under control. You also need to be well enough in your general health to undergo the cell collection and infusion processes.

You may not be able to take part if you have active, uncontrolled infections, severe heart, lung, or kidney failure unrelated to your condition, or if you are pregnant or breastfeeding. Your hospital specialist will carry out comprehensive health checks and blood tests to confirm whether the trial is safe and appropriate for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have been diagnosed with a severe autoimmune condition (e.g. lupus, scleroderma, myasthenia gravis) or chronic graft-versus-host disease.
  3. My current treatments and steroid medicines are no longer working well enough.
  4. I am well enough to attend hospital visits and undergo cell collection and blood tests.
  5. I do not have an active, serious infection.
Answer every question to see your result.

What does participation involve?

Taking part in this study involves several distinct steps over approximately one year. First, you will undergo thorough health screenings, including blood tests and scans. Next, you will have a procedure called apheresis, where blood is drawn through a machine to collect your T cells before returning the rest of your blood to you. You will then wait a few weeks while your cells are modified in a laboratory.

Before receiving your cells, you will have a short course of mild chemotherapy over a few days to prepare your body. You will then receive your modified CAR T-cells through a drip. Because side effects most often occur shortly after the infusion, you will stay in hospital for close observation during the first few weeks. Afterwards, you will attend regular outpatient check-ups over 48 weeks to monitor your blood counts, manage any side effects, and see how well your condition is responding.

Potential risks and benefits

The potential benefit of taking part is that the treatment may help calm your immune system, improve your daily symptoms, and allow you to reduce or stop taking steroid medications. However, because this is an early-stage trial, direct benefits cannot be guaranteed. There are also risks to consider. CAR T-cell therapy can trigger strong immune reactions that cause high fevers, flu-like aches, or temporary confusion. Because the treatment temporarily clears your normal B cells, you will also be at a higher risk of infections for several months. Taking part is entirely voluntary, and you are free to leave the trial at any time without your regular NHS care being affected.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Italy

Common questions

What is a 'basket trial'?

A basket trial is a type of clinical study that tests a single treatment on several different conditions that all share a common biological feature—in this case, faulty B cells.

Will I have to stay in hospital?

Yes. You will usually need to stay in hospital for the cell infusion and for the first few weeks afterwards so doctors can watch closely for any fevers or other side effects.

Can I choose what dose of cells I receive?

No. In early safety trials, doses are assigned according to a strict medical plan to safely test how much of the therapy can be given without causing severe side effects.

Will I be able to stop my current steroid tablets?

One of the main aims of the study is to see if patients can safely stop steroids, but any changes to your medication will be made very gradually under close doctor supervision.

What happens if the therapy does not work for me?

If your condition does not improve, your medical team will discuss other standard care pathways and alternative treatments to keep your symptoms managed.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.